Every Form 4 that Metsera, Inc. (MTSR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MTSR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MTSR filings page.
Metsera, Inc. reported insider changes tied to its merger with Pfizer Inc., where all reported Metsera common shares were converted into cash and contingent value rights. The filing shows that indirect holdings reported through F-Prime Inc. and other related persons and entities went to zero following transactions dated 11/13/2025. Under the merger agreement among Metsera, Pfizer and Mayfair Merger Sub, each share of Metsera common stock was converted into the right to receive $65.60 in cash per share, net of applicable withholding taxes, plus one contractual contingent value right providing for potential additional cash payments if specified milestones are achieved.
Metsera, Inc. (MTSR) reported insider transactions tied to its merger with Pfizer. On 11/13/2025, each share of Metsera common stock was converted into the right to receive $65.60 in cash per share plus one contingent value right (CVR) under the merger terms.
The Chief Medical Officer reported disposition of 17,000 common shares, leaving 0 shares beneficially owned. Outstanding stock options were canceled for cash based on the $65.60 closing amount and CVRs per share covered, including options over 120,000 shares (exercise price $29.25) and options over 829,885 and 21,279 shares (exercise price $0.26). RSUs were also canceled and converted into cash based on the closing amount and an equivalent number of CVRs, with vesting terms preserved under the agreement.
Metsera (MTSR) filed a Form 4 tied to its merger with Pfizer. The filing states each Metsera common share was converted into $65.60 in cash plus one contingent value right (CVR) at closing. The reporting director recorded merger-related dispositions of common stock and the cancellation of equity awards in exchange for the cash consideration and CVRs.
On 11/13/2025, outstanding stock options were canceled for cash (based on the $65.60 closing amount minus the exercise price) and CVRs; RSUs were canceled for cash at $65.60 per underlying share and CVRs. The table shows 4,031 RSUs, and stock options covering 24,188 and 223,430 shares, all settled, with reported post‑transaction holdings shown as zero in the listed entries.
Metsera, Inc. (MTSR) filed a Form 4 for its Chief Legal Officer detailing equity conversions arising from the closing of its merger with Pfizer. At the effective time, each common share converted into $65.60 in cash per share plus one contingent value right (CVR) tied to specified milestones.
The filing reports the disposition of 12,500 shares of common stock, leaving 0 shares beneficially owned. It also shows 12,500 RSUs subject to conversion into cash at the $65.60 closing amount per underlying share plus CVRs, following their original vesting schedule. In addition, stock options for 46,875 shares (exercise price $29.25) and 325,000 shares (exercise price $17.16) were canceled and exchanged for cash equal to the in-the-money value based on the $65.60 closing amount, plus CVRs per underlying share. Unvested awards maintain vesting terms, with merger-related vesting described to occur by the first anniversary, subject to continued service.
Metsera, Inc. (MTSR) reported insider transactions on Form 4 tied to its merger closing with Pfizer on 11/13/2025. At the effective time, each issued and outstanding Metsera common share was converted into the right to receive $65.60 in cash per share, plus one contingent value right (CVR) payable upon specified milestones.
The filing lists holdings associated with Population Health Partners: 12,639,787 shares recorded by Population Health Partners, L.P. and 127,675 shares recorded by Population Health Partners GP, LLC. Following the reported transaction, the filing shows 0 shares beneficially owned by the reporting person.
Metsera (MTSR) reported insider transactions tied to its merger with Pfizer effective on 11/13/2025. At closing, each share of Metsera common stock converted into the right to receive $65.60 in cash per share, plus one contingent value right (CVR) payable in cash upon achievement of specified milestones.
Equity awards were also settled under the merger terms. Outstanding stock options were canceled for a cash payment equal to the excess of $65.60 over the exercise price, multiplied by the number of underlying shares, plus one CVR per underlying share; unvested awards follow their schedule but fully vest on the first anniversary of closing, subject to continued service. RSUs were canceled for cash equal to $65.60 per underlying share plus the same number of CVRs, with no vesting conditions on those payments. The filing reflects director Kristina M. Burow’s positions, including indirect interests disclosed through ARCH Venture funds.
Metsera, Inc. (MTSR): Validae Health, L.P. filed a Form 4 reporting a Code J transaction involving the distribution of 12,767,462 shares of Metsera common stock at $0 on November 11, 2025. Following the transaction, the filer reported 0 shares directly owned.
Footnotes state Validae distributed 99% of its Metsera shares to Population Health Partners, L.P. and 1% to Population Health Partners GP, LLC. PHP GP LLC may be deemed to beneficially own shares held by Validae and PHP LP; certain individuals are members of PHP GP LLC and may share dispositive and voting power, with beneficial ownership disclaimed except to the extent of pecuniary interest.
Metsera (MTSR) filed a Form 4 reflecting transactions tied to its merger with Pfizer. At closing, each share of Metsera common stock converted into the right to receive $65.60 in cash per share plus one contingent value right (CVR), per the merger terms.
The reporting person recorded an acquisition of 2,688 RSUs on November 12, 2025, which were then canceled and converted into cash at the Closing Amount and an equal number of CVRs. Outstanding stock options were canceled in exchange for cash equal to intrinsic value and one CVR per underlying share; unvested awards follow prior schedules with vesting on the first merger anniversary subject to continued service. Following these transactions, the Form 4 shows 0 shares of common stock beneficially owned.
Metsera, Inc. (MTSR) filed a Form 4 reflecting transactions tied to its merger with Pfizer Inc.. At the merger’s Effective Time, each share of Metsera common stock was converted into the right to receive $65.60 in cash per share, plus one contingent value right (CVR) payable in cash upon specified milestones.
The reporting person’s holdings changed accordingly: 2,688 shares of common stock were disposed, leaving 0 shares beneficially owned. A restricted stock unit grant of 2,688 RSUs was reported; under the merger, RSUs were canceled and converted into cash equal to the cash amount per share times the RSU count and CVRs equal to the underlying shares, with these payments not subject to vesting. A stock option for 47,730 shares at $19.81 was canceled and exchanged for cash based on the excess of the cash amount over the exercise price, plus one CVR per underlying share. For unvested options, the cash and CVRs will vest on the first anniversary of closing, contingent on continued service.
Metsera, Inc. (MTSR) filed a Form 4 detailing insider transactions tied to its merger with Pfizer. The filing states each share of common stock was converted into the right to receive $65.60 per share plus one contingent value right (CVR).
Chief Scientific Officer Brian Hubbard reported the disposal of 17,000 shares, with 0 shares owned afterward. Outstanding stock options were cancelled for cash equal to any in‑the‑money value plus CVRs, including options covering 319,186 shares at $0.26, 120,000 at $29.25, and 106,395 at $8.18. A grant of 17,000 RSUs on November 12, 2025 was converted to cash at the Closing Amount and CVRs. Unvested cash and CVR amounts vest on the first anniversary of the merger.
Metsera (MTSR) CFO filed a Form 4 detailing equity conversion and cancellation tied to the Pfizer merger. At closing, each Metsera common share was converted into the right to receive $65.60 in cash per share plus one contingent value right (CVR), as described in the merger terms.
The filing shows disposition of 21,250 shares of common stock, leaving 0 shares beneficially owned after the transaction. It also records the award and conversion of 21,250 RSUs, which became the right to receive cash based on $65.60 per underlying share and an equal number of CVRs, subject to the original vesting schedule. All stock options were canceled in exchange for cash equal to any in-the-money value plus one CVR per underlying share, including grants for 150,000 options at $29.25, 255,349 at $4.33, and 340,465 at $8.18, each with 0 remaining after the merger mechanics.
Metsera (MTSR) insider filing: Executive Chairman and Director reported transactions on 11/13/2025 tied to the closing of the Pfizer merger. Each Metsera common share was converted into the right to receive $65.60 in cash per share plus one contingent value right (CVR).
Outstanding stock options were cancelled for cash based on the excess of $65.60 over the exercise price, plus CVRs per underlying share. Reported option positions included 32,250 options at $29.25 (expiring 05/19/2035) and 297,907 options at $8.18 (expiring 11/11/2034). Previously granted 5,375 RSUs were cancelled for cash at $65.60 per unit plus CVRs.
Metsera (MTSR) filed a Form 4 reporting transactions tied to its merger with Pfizer. At closing, each Metsera common share was converted into the right to receive $65.60 in cash plus one contingent value right (CVR). Outstanding stock options were canceled for a cash amount based on the in‑the‑money value using the $65.60 price, plus one CVR per underlying share. RSUs were canceled for cash at $65.60 per unit and an equal number of CVRs. Unvested option and RSU payouts continue on their original schedules and become fully vested on the first anniversary of the merger, subject to continued service. Following the transactions, 12,767,462 shares are shown as indirectly beneficially owned through Population Health Partners entities.
Metsera, Inc. (MTSR) reported a Form 4 showing a bona fide gift of 860,722 shares of common stock on 11/10/2025 at a reported price of $0 (Transaction Code G). After this disposition, the reporting person beneficially owned 2,230,450 shares indirectly.
The filing also lists 3,010 shares held indirectly through F-Prime Inc. The reporting person is identified as a Director and Officer.
Metsera, Inc. (MTSR): Insider ownership reallocation and small sale reported. A reporting person and affiliated entities recorded multiple “J” code transactions on 11/03/2025, which the filing explains were distributions without payment of consideration. These moved shares among related entities and did not reflect purchase or sale prices.
The filing also shows a small open-market sale: 193 shares at $61.2281 by Impresa Fund IV LLC. Following the transactions, indirect beneficial holdings include 3,091,172 shares “held by persons and entities whose shares are subject to reporting by the undersigned,” 47,843 shares held by F‑Prime Capital Partners Life Sciences Advisors Fund VIII LP, and 3,010 shares held by F‑Prime Inc.
FMR LLC filed a Form 4 reporting insider changes in Metsera, Inc. (MTSR). On 10/06/2025 a disposition of 633,715 common shares was reported with a price shown as $0.00. After the reported transaction, the filing shows 473,832 shares beneficially owned indirectly. The filing identifies relationships linking Abigail P. Johnson to FMR LLC and notes various indirect holdings through F-Prime entities and funds.